Generic

Apotex challenges Amgen blockbuster Neulasta

Canadian firm presents FDA with its third biosimilar application.

Bayer loses cancer drug patent fight in India

Court clears the way for a Nexavar generic from Natco

Pfizer's Celebrex slammed by entry of generics

Mylan, Teva, and Actavis announced generics of the $3 billion arthritis drug.

Five things for pharma marketers to know: Wednesday, December 10

Five things for pharma marketers to know: Wednesday, December 10

By

Cubist's best-selling product has four of its five patents invalidated; the first biologic of AbbVie's Humira launches in India; Mylan debuts generic Celebrex.

Actavis launches generic of Intuniv

The first low-cost version of the Shire ADHD drug benefits as a first-filer.

Five things for pharma marketers to know: Tuesday, November 25

Five things for pharma marketers to know: Tuesday, November 25

By By

AstraZeneca and Ranbaxy pay-for-delay case marches on; FDA extends Novartis multiple myeloma Priority Review timeline; Endo pays $25 for testosterone nasal gel.

FDA delays rule on generic drug labeling amid controversy

As generic drug use soars, the agency intends to "create parity" in label-change rules for brands and generics.

Five things for pharma marketers to know: Tuesday, November 18

Five things for pharma marketers to know: Tuesday, November 18

By By

Ackman walks away with $2.5 billion, despite no Allergan deal; Ranbaxy sues FDA over generic Nexium rights; Indian government's Health Ministry recommends breaking BMS cancer drug patent.

Five things for pharma marketers to know: Friday, November 14

Five things for pharma marketers to know: Friday, November 14

By By

Pfizer reportedly not interested in acquiring AZ; high deductible plans set to envelop healthcare insurance exchanges; GSK's mature drug portfolio finds a wholesale suitor.

Lawmakers float generic drug legislation

The bill proposes fining branded drugmakers for not complying.

Lawmakers float generic drug legislation

The bill proposes fining branded drugmakers for not complying.

Missing generic hurts Rite Aid

The drugstore chain has lowered its forecast, and generics are just one reason.

Mylan buys branded and generic Arixtra

The $225-million deal will give Mylan one of two generics for the deep vein thrombosis drug.

FDA sanctions don't kill a business

Bloomberg reports that India's Wockhardt has become an M&A target.

FDA sanctions don't kill a business

Bloomberg reports that India's Wockhardt has become an M&A target.

Generic Viagra floods Brazil

The generic ED pills sell for five cents less than Pfizer's branded blue pill, but the undercutting is a bit deeper.

UK generic use soared in 2013

Generics made up almost 75% of prescriptions in the United Kingdom last year.

FDA generic division overhaul kicks in

The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.

Visual continuity key to patient adherence

Visual continuity key to patient adherence

By

Researchers at the Brigham and Women's Hospital found that continuity in color and shape have a significant impact on whether patients stick with a prescription regimen.

Abbott pairs generics with tax benefit

Abbott and Mylan are setting up a generics business. The all-stock deal will give some branded generics a new home and offer Abbott a tax benefit that will increase over time.

Abbott pairs generics with tax benefit

Abbott and Mylan are setting up a generics business. The all-stock deal will give some branded generics a new home and offer Abbott a tax benefit that will increase over time.

Generics trigger wallet shock

Prices for some generics are rising, thanks to limited competition.

EU fines six for pay-for-delay

Servier and Teva have been fined for keeping a generic heart medication off the market.

Sun recalls cancer drug

It's the generics maker's second recall of 2014.

India's generics makers hire Beltway help

The Indian Pharmaceutical Alliance makes a bid for legislators' attention.

Diovan competition is coming

Novartis no longer has a lock on the Diovan market: the FDA approved Ranbaxy's generic, which will be made in the US.

Sun's FDA Warning Letter

Sun's FDA Warning Letter

By

The FDA's seven-page letter outlines some of the problems the regulator has with one specific Sun site.

FDA seeks math of similarity

A three-year, $1 million project seeks an equation for generics and biosimilars.

Generic Copaxone is coming

Teva lost its most recent fight to keep generics of Copaxone off the market.

Court won't stall generic Copaxone

Court won't stall generic Copaxone

By

The Supreme Court denied Teva's request to keep branded Copaxone off the market while the appeals process shakes out.


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.

Email Newsletters